Inhaled Interventions in Cystic Fibrosis: Mucoactive and Antibiotic Therapies

被引:16
作者
Hurt, Katharine [1 ]
Bilton, Diana [2 ,3 ]
机构
[1] Brighton & Sussex Univ Hosp, Brighton, E Sussex, England
[2] Royal Brompton Hosp, London SW3 6LY, England
[3] Univ London Imperial Coll Sci Technol & Med, London, England
关键词
Cystic fibrosis; Inhaled antibiotics; Hyperosmolar therapy; Mucolytic therapy; RECOMBINANT HUMAN DNASE; DRY-POWDER MANNITOL; PSEUDOMONAS-AERUGINOSA; AZTREONAM LYSINE; DORNASE-ALPHA; INHALATION; TOBRAMYCIN; EFFICACY; DISEASE; MODEL;
D O I
10.1159/000369533
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Treatment of cystic fibrosis lung disease has developed from an understanding of the abnormal airway surface liquid resulting from a lack of function of the cystic fibrosis transmembrane regulator protein. Mucus plugging resulting in infection and inflammation leads to airway wall destruction and bronchiectasis. Inhaled therapies have formed the backbone of treatments. In combination with antibiotics delivered direct to the airway, mucoactive drugs, including mucolytics and hyperosmolar agents, are utilised to improve mucociliary clearance to reduce infection and inflammation. Until recently, airway therapies were delivered as nebulisers, but we have now entered the era of dry powder inhalers for treatment of cystic fibrosis lung disease. The theory and practice of these therapies are discussed in this review. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:441 / 448
页数:8
相关论文
共 50 条
[41]   New Therapies in Cystic Fibrosis [J].
Ratjen, Felix ;
Grasemann, Hartmut .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (05) :614-627
[42]   Inhaled Aztreonam Lysine for Cystic Fibrosis Pulmonary Disease-Related Outcomes [J].
Pesaturo, Kimberly A. ;
Horton, Evan R. ;
Belliveau, Paul .
ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) :1076-1085
[43]   Use of Inhaled Tobramycin in Cystic Fibrosis [J].
Michal Shteinberg ;
J. Stuart Elborn .
Advances in Therapy, 2015, 32 :1-9
[44]   Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis [J].
Elborn, J. Stuart ;
Flume, Patrick A. ;
Van Devanter, Donald R. ;
Procaccianti, Claudio .
FUTURE MICROBIOLOGY, 2021, 16 (14) :1087-1104
[45]   Inhaled Biologicals for the Treatment of Cystic Fibrosis [J].
Sala, Valentina ;
Murabito, Alessandra ;
Ghigo, Alessandra .
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2019, 13 (01) :19-26
[46]   CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis [J].
Saluzzo, Francesca ;
Riberi, Luca ;
Messore, Barbara ;
Lore, Nicola Ivan ;
Esposito, Irene ;
Bignamini, Elisabetta ;
De Rose, Virginia .
CELLS, 2022, 11 (07)
[47]   Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin [J].
Ehsan, Zarmina ;
Clancy, John P. .
FUTURE MICROBIOLOGY, 2015, 10 (12) :1901-1912
[48]   Aztreonam Lysine Inhalation Solution in Cystic Fibrosis [J].
Elson, Elizabeth Claire ;
Mermis, Joel ;
Polineni, Deepika ;
Oermann, Christopher M. .
CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2019, 13
[49]   Medical interventions for chronic rhinosinusitis in cystic fibrosis [J].
Karanth, Tulasi Kota ;
Karanth, Veena Kota Laxminarayan K. L. ;
Ward, Bryan K. ;
Woodworth, Bradford A. ;
Karanth, Laxminarayan .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (04)
[50]   Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data [J].
Hamed, Kamal ;
Conti, Valentino ;
Tian, Hengfeng ;
Loefroth, Emil .
PATIENT PREFERENCE AND ADHERENCE, 2017, 11 :831-838